知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.018 秒)

    Immunogenic constructs
    1.
    发明授权
    Immunogenic constructs 有权
    免疫原性构建体

    公开(公告)号：US07892566B2

    公开(公告)日：2011-02-22

    申请号：US11997627

    申请日：2006-08-03

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： A61K39/04

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/545 ,  C07K14/35 ,  C12N2799/022 ,  C12N2799/023 ,  Y10S435/975

    摘要： The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a pl2 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide.

    摘要翻译： 本发明涉及可用于诱导针对MAP的治疗或预防性免疫应答的分子。 特别地，本发明涉及包含alipC多肽序列，gsd多肽序列，p12多肽序列和mpa多肽序列的多肽，其中所述ahpC多肽包含SEQ ID NO：2的序列，其变体具有多于 SEQ ID NO：2的全长与SEQ ID NO：2的70％氨基酸序列同一性，或包含SEQ ID NO：2的至少8个氨基酸的片段; 所述gsd多肽包含SEQ ID NO：6的序列，其在SEQ ID NO：6的全长上与SEQ ID NO：6具有超过70％的氨基酸序列同一性的变体，或至少8个氨基的片段 包含表位的SEQ ID NO：6的酸; 所述pi 2多肽包含SEQ ID NO：10的序列，其在SEQ ID NO：10全长与SEQ ID NO：10具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：10的氨基酸; 并且所述mpa多肽包含SEQ ID NO：14的序列，其在SEQ ID NO：14全长与SEQ ID NO：14具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：14的氨基酸。 优选地，这种变体保持产生针对未修饰多肽的免疫应答的能力。

    Zymogen activation peptides (ZAP) in the diagnosis of disease
    2.
    发明授权
    Zymogen activation peptides (ZAP) in the diagnosis of disease 失效
    酶原激活肽（ZAP）在疾病诊断中的应用

    公开(公告)号：US5356781A

    公开(公告)日：1994-10-18

    申请号：US721234

    申请日：1991-06-26

    申请人： John Hermon-Taylor ,  Brian M. Austen

    发明人： John Hermon-Taylor ,  Brian M. Austen

    IPC分类号： G01N33/573 ,  G01N33/68 ,  G01N33/543 ,  C07K7/06 ,  C12N9/96 ,  C07K14/00

    CPC分类号： G01N33/6893 ,  G01N33/573 ,  G01N2800/067 ,  Y10S435/81 ,  Y10S530/845

    摘要： Pancreatic disease can be diagnosed by assaying a patient's body fluid such as serum or urine, for pancreatic activation peptides (PAP) released from zymogens by proteolytic activation. Particularly useful are peptides having C-terminal D.sub.4 K sequences. The method uses polyclonal or monoclonal antibodies generated and selected for C-terminal specificity on PAP so that the tests only report free PAP not parent zymogen. Also described are peptides and antibodies labelled with revealing agents and/or immobilised on solid supports and their use in diagnostic assays and kits. In pancreatic disease the tests distinguish necrotising from oedematous acute pancreatitis and permit severity prediction and monitoring as well as diagnosing chronic pancreatitis in exacerbation. Tests reporting free activation peptides from the zymogens prophospholipase A, procolipase and proelastases are also applicable in non-pancreatic diseases where activation of these zymogens, sharing sequence homology in the activation peptide C-terminal region with pancreatic isoenzymes, forms part of the molecular pathology of the condition.

    摘要翻译： 可以通过测定患者的体液如血清或尿液，通过蛋白水解活化从酶原释放的胰激活肽（PAP）来诊断胰腺疾病。 特别有用的是具有C末端D4K序列的肽。 该方法使用产生并选择用于PAP的C-末端特异性的多克隆或单克隆抗体，使得测试仅报告游离PAP不是母体酶原。 还描述了用显露剂标记和/或固定在固体支持物上的肽和抗体及其在诊断测定和试剂盒中的用途。 在胰腺疾病中，这种检测将坏死性坏死性急性胰腺炎分为坏死因子，并允许严重程度预测和监测以及诊断恶化的慢性胰腺炎。 报道酶原磷脂酶A，原纤维蛋白酶和原弹药蛋白酶的自由激活肽的测试也适用于非胰腺疾病，其中这些酶原激活在激活肽C-末端区域与胰同型酶共享序列同源性，形成分子病理学的一部分 条件。

    Immunogenic Constructs
    6.
    发明申请
    Immunogenic Constructs 有权
    免疫原性构建体

    公开(公告)号：US20110129502A1

    公开(公告)日：2011-06-02

    申请号：US13007062

    申请日：2011-01-14

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： A61K39/04 ,  C07K14/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  A61K31/7088 ,  A61P31/04

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/545 ,  C07K14/35 ,  C12N2799/022 ,  C12N2799/023 ,  Y10S435/975

    摘要： The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide.

    摘要翻译： 本发明涉及可用于诱导针对MAP的治疗或预防性免疫应答的分子。 特别地，本发明涉及包含alipC多肽序列，gsd多肽序列，p12多肽序列和mpa多肽序列的多肽，其中所述ahpC多肽包含SEQ ID NO：2的序列，其变体具有多于 SEQ ID NO：2的全长与SEQ ID NO：2的70％氨基酸序列同一性，或包含SEQ ID NO：2的至少8个氨基酸的片段; 所述gsd多肽包含SEQ ID NO：6的序列，其在SEQ ID NO：6的全长上与SEQ ID NO：6具有超过70％的氨基酸序列同一性的变体，或至少8个氨基的片段 包含表位的SEQ ID NO：6的酸; 所述pi 2多肽包含SEQ ID NO：10的序列，其在SEQ ID NO：10全长与SEQ ID NO：10具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：10的氨基酸; 并且所述mpa多肽包含SEQ ID NO：14的序列，其在SEQ ID NO：14全长与SEQ ID NO：14具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：14的氨基酸。 优选地，这种变体保持产生针对未修饰多肽的免疫应答的能力。

    Immunogenic Constructs
    7.
    发明申请
    Immunogenic Constructs 有权
    免疫原性构建体

    公开(公告)号：US20090203593A1

    公开(公告)日：2009-08-13

    申请号：US11997627

    申请日：2006-08-03

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： A61K38/16 ,  C07K14/00 ,  C12N15/11 ,  C12N15/00 ,  C12N1/21 ,  A61K31/7088

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/545 ,  C07K14/35 ,  C12N2799/022 ,  C12N2799/023 ,  Y10S435/975

    摘要： The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide.

    摘要翻译： 本发明涉及可用于诱导针对MAP的治疗或预防性免疫应答的分子。 特别地，本发明涉及包含alipC多肽序列，gsd多肽序列，p12多肽序列和mpa多肽序列的多肽，其中所述ahpC多肽包含SEQ ID NO：2的序列，其变体具有多于 SEQ ID NO：2的全长与SEQ ID NO：2的70％氨基酸序列同一性，或包含SEQ ID NO：2的至少8个氨基酸的片段; 所述gsd多肽包含SEQ ID NO：6的序列，其在SEQ ID NO：6的全长上与SEQ ID NO：6具有超过70％的氨基酸序列同一性的变体，或至少8个氨基的片段 包含表位的SEQ ID NO：6的酸; 所述pi 2多肽包含SEQ ID NO：10的序列，其在SEQ ID NO：10全长与SEQ ID NO：10具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：10的氨基酸; 并且所述mpa多肽包含SEQ ID NO：14的序列，其在SEQ ID NO：14全长与SEQ ID NO：14具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：14的氨基酸。 优选地，这种变体保持产生针对未修饰多肽的免疫应答的能力。

    Diagnostics and vaccines for mycobacterial infections of animals and humans
    8.
    发明授权
    Diagnostics and vaccines for mycobacterial infections of animals and humans 有权
    用于动物和人类分枝杆菌感染的诊断和疫苗

    公开(公告)号：US08148136B1

    公开(公告)日：2012-04-03

    申请号：US09646568

    申请日：1999-03-18

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： C07H21/04 ,  C07H21/02 ,  C12N1/12 ,  C12N1/20 ,  C12N15/00 ,  A01N63/00 ,  A01N65/00 ,  A61K48/00

    CPC分类号： C12N9/18 ,  A61K39/00 ,  A61K48/00 ,  Y10S435/863 ,  Y10S435/864

    摘要： This invention relates to the protein, Mycobacterium paratuberculosis acylase (mpa) and the gene encoding mpa, which we have identified in the pathogen Mycobacterium paratuberculosis Mptb (also designated Mycobacterium avium subspecies paratuberculosis MAP), and to their use in the diagnosis of Mptb/MAP infections in animals and humans, as well as their use as components of vaccines for the prevention and treatment of diseases caused by Mptb/MAP. The importance of an intact uninterrupted mpa gene as a determinant of pathogenicity in Mptb/MAP is recognized and the invention also provides attenuated strains of normally pathogenic Mptb/MAP and other mycobacteria in which mpa has been inactivated, for use as vaccines.

    摘要翻译： 本发明涉及蛋白质，副结核分枝杆菌酰基转移酶（mpa）和编码mpa的基因，我们在病原体分枝杆菌（Mycobacterium paratuberculosis）Mptb（也称为鸟分枝杆菌亚种paratuberculosis MAP）中鉴定，并且用于诊断Mptb / MAP 动物和人类的感染，以及它们作为预防和治疗由Mptb / MAP引起的疾病的疫苗的组成部分的用途。 认识到完整的不间断mpa基因作为Mptb / MAP中致病性决定簇的重要性，本发明还提供通常致病的Mptb / MAP和其它mpa已被灭活的分解细菌的减毒菌株，用作疫苗。

    Immunogenic constructs
    9.
    发明授权
    Immunogenic constructs 有权
    免疫原性构建体

    公开(公告)号：US08147850B2

    公开(公告)日：2012-04-03

    申请号：US13007062

    申请日：2011-01-14

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： A61K39/04

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/545 ,  C07K14/35 ,  C12N2799/022 ,  C12N2799/023 ,  Y10S435/975

    摘要： The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide.

    摘要翻译： 本发明涉及可用于诱导针对MAP的治疗或预防性免疫应答的分子。 特别地，本发明涉及包含alipC多肽序列，gsd多肽序列，p12多肽序列和mpa多肽序列的多肽，其中所述ahpC多肽包含SEQ ID NO：2的序列，其变体具有多于 SEQ ID NO：2的全长与SEQ ID NO：2的70％氨基酸序列同一性，或包含SEQ ID NO：2的至少8个氨基酸的片段; 所述gsd多肽包含SEQ ID NO：6的序列，其在SEQ ID NO：6的全长上与SEQ ID NO：6具有超过70％的氨基酸序列同一性的变体，或至少8个氨基的片段 包含表位的SEQ ID NO：6的酸; 所述pi 2多肽包含SEQ ID NO：10的序列，其在SEQ ID NO：10全长与SEQ ID NO：10具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：10的氨基酸; 并且所述mpa多肽包含SEQ ID NO：14的序列，其在SEQ ID NO：14全长与SEQ ID NO：14具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：14的氨基酸。 优选地，这种变体保持产生针对未修饰多肽的免疫应答的能力。